A novel mechanism for skeletal resistance in uremia

Slides:



Advertisements
Similar presentations
Volume 68, Pages S24-S28 (July 2005)
Advertisements

Volume 79, Pages S3-S8 (April 2011)
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
G1 kinases and transforming growth factor-β; signaling are associated with a growth pattern switch in diabetes-induced renal growth  Hai-Chang Huang,
E. Cavalier, P. Delanaye, A. Carlisi, J. -M. Krzesinski, J. -P
Volume 60, Issue 6, Pages (December 2001)
Volume 67, Pages S1-S7 (June 2005)
Volume 64, Issue 3, Pages (September 2003)
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Volume 55, Issue 3, Pages (March 1999)
Parathyroid hormone measurement in CKD
Circulating biochemical markers of bone remodeling in uremic patients
Volume 62, Issue 2, Pages (August 2002)
Chapter 3.1: Diagnosis of CKD–MBD: biochemical abnormalities
Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients  Demetrios J. Kutsogiannis, R.T.Noel.
RenaGel®, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone  Eduardo A. Slatopolsky, Steven K.
Volume 78, Issue 10, Pages (November 2010)
Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali.
Volume 67, Issue 2, Pages (February 2005)
TGF-β isoforms in renal fibrogenesis
Volume 79, Pages S3-S8 (April 2011)
Differential effects of 19-nor-1,25-(OH)2D2 and 1α-hydroxyvitamin D2 on calcium and phosphorus in normal and uremic rats  Eduardo Slatopolsky, Mario Cozzolino,
Volume 60, Issue 6, Pages (December 2001)
Volume 76, Pages S50-S99 (August 2009)
Volume 64, Issue 2, Pages (August 2003)
Volume 70, Pages S12-S15 (July 2006)
Effects of antihypertensive therapy on intrarenal angiotensin and bradykinin levels in experimental renal insufficiency  Fiona E. Mackie, Timothy W. Meyer,
Volume 64, Issue 5, Pages (November 2003)
Circulating PTH molecular forms: What we know and what we don't
Influence of parathyroid mass on the regulation of PTH secretion
New vitamin D analogs Kidney International
Correction to "Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate.
Ewa Lewin, Yolanda Almaden, Mariano Rodriguez, Klaus Olgaard 
Volume 80, Issue 5, Pages (September 2011)
Volume 63, Issue 1, Pages 1-11 (January 2003)
Volume 69, Issue 3, Pages (February 2006)
James D. House, Margaret E. Brosnan, John T. Brosnan 
Volume 68, Pages S24-S28 (July 2005)
Impact of gender on the renal response to angiotensin II
Volume 59, Issue 3, Pages (March 2001)
Volume 56, Issue 2, Pages (August 1999)
Starting dialysis is dangerous: how do we balance the risk?
Pathogenesis of refractory secondary hyperparathyroidism
Volume 68, Issue 4, Pages (October 2005)
Volume 68, Issue 3, Pages (September 2005)
Volume 80, Issue 3, Pages (August 2011)
Volume 57, Issue 4, Pages (April 2000)
Volume 54, Issue 1, Pages (July 1998)
Volume 56, Issue 3, Pages (September 1999)
Volume 80, Issue 10, Pages (November 2011)
Increased parathyroid expression of klotho in uremic rats
Volume 56, Issue 2, Pages (August 1999)
Volume 66, Issue 6, Pages (December 2004)
Volume 64, Issue 1, Pages (July 2003)
Recent developments in the management of secondary hyperparathyroidism
Volume 58, Issue 2, Pages (August 2000)
Volume 56, Issue 5, Pages (November 1999)
Volume 56, Issue 1, Pages (July 1999)
Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease  Aquiles Jara, Arnold J. Felsenfeld, Jordi.
Volume 53, Issue 5, Pages (May 1998)
Volume 60, Issue 5, Pages (November 2001)
Control of uremic bone disease: Role of vitamin D analogs
Volume 55, Issue 5, Pages (May 1999)
Volume 55, Issue 4, Pages (April 1999)
Volume 61, Issue 4, Pages (April 2002)
Mary B. Leonard, Lynn A. Donaldson, Martin Ho, Denis F. Geary 
Kidney and hypertension
Volume 71, Issue 8, Pages (April 2007)
Volume 87, Issue 6, Pages (June 2015)
Volume 86, Issue 2, Pages (August 2014)
Presentation transcript:

A novel mechanism for skeletal resistance in uremia Eduardo Slatopolsky, Jane Finch, Patricia Clay, Daniel Martin, Gregorio Sicard, Gary Singer, Ping Gao, Thomas Cantor, Adriana Dusso  Kidney International  Volume 58, Issue 2, Pages 753-761 (August 2000) DOI: 10.1016/S0085-2538(15)47156-X Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 1 Immunodetection of parathyroid hormone (PTH) by the Whole PTH and Nichols Intact PTH (I-PTH) assays. In both assays, the immobilized antibody recognizes a large portion of the C/midregion of the PTH molecule. However, in the Whole PTH assay (top), the labeled antibody recognizes only the first six amino acids, while the labeled antibody from the typical I-PTH assay (bottom) recognizes a larger number of amino acids in the N-terminal region. Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 2 Comparison of the recognition of hPTH 1-84 and hPTH 7-84 by the Nichols I-PTH assay. The Nichols I-PTH assay does not differentiate between hPTH 1-84 (solid line) and hPTH 7-84 (dashed line). Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 3 Comparison of the recognition of hPTH 1-84 and hPTH 7-84 by the Whole PTH assay. Unlike the Nichols I-PTH assay, the Whole PTH assay does discriminate between hPTH 1-84 (solid line) and hPTH 7-84 (dashed line). Concentrations of hPTH 7-84 as high as 10,000 pg were undetectable. Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 4 Comparison of the effect of hPTH 1-84 or hPTH 7-84 on cAMP production in ROS 17.2 cells. Unlike hPTH 7-84, hPTH 1-84 increased cAMP production in a dose-dependent manner. cAMP increased from 18.1 ± 1.2 to 738 ± 4.1 nmol/well after treatment with 10-8 mol/L hPTH 1-84. The same concentration of hPTH 7-84 had no effect. Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 5 Comparison of the calcemic effects of PTH isoforms. Parathyroidectomized (PTX) rats fed a 0.02% calcium diet show a significant increase in plasma calcium after treatment with hPTH 1-84. In contrast, hPTH 7-84 produced a slight but significant decrease in plasma calcium. When both peptides were given together in a 1:1 molar ratio, the calcemic response induced by hPTH 1-84 was reduced by 94% (P < 0.001). Symbols are: (•) 1-84, N = 9; (▪) 1-84 + 7-84, N = 6; (▴) Control, N = 5; (♦) 7-84, N = 5. Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 6 Comparison of the effects of hPTH 1-84 or hPTH 1-84 plus hPTH 7-84 on (A) glomerular filtration rate (GFR) and (B) fractional excretion of phosphorus (FEPO4). Control and treatment periods are denoted by open and closed bars, respectively. The phosphaturia induced by hPTH 1-84 was decreased by 50.2% (P < 0.05) when animals were treated simultaneously with 7-84 PTH, despite a significant increase in GFR (P < 0.005). Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 7 Comparison of PTH values in plasma from uremic patients using the Nichols “intact” PTH assay (▪) versus the Whole PTH assay (•). Plasma PTH values are uniformly higher when measured with the Nichols “intact” PTH assay than with the Whole PTH assay. The median PTH values were 523 vs. 344 pg/mL, respectively (P < 0.001). Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 8 Regression analysis of plasma PTH measured by Nichols I-PTH and Whole PTH assay in uremic patients (r = 0.97; P < 0.001). Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 9 Effects of plasma calcium on PTH degradation in dialysis patients. The percentage of non-(1-84) PTH fragment (likely hPTH 7-84) correlates positively with plasma calcium (P < 0.02) (r = 0.638; P = 0.0025; N = 20). Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 10 Comparison of plasma PTH levels in renal transplant patients using Nichols I-PTH and Whole PTH assays. PTH values are higher when measured with the Nichols I-PTH assay (P < 0.005). Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions

Figure 11 Intracellular PTH content in parathyroid glands from uremic patients. The 41.8 ± 3.2% of the total PTH, measured by the I-Nichols assay (expressed as 100%), represents the non-(1-84) PTH fragment “likely” hPTH 7-84 (□). The 1-84 PTH molecule was measured with the Whole PTH assay (▪). Kidney International 2000 58, 753-761DOI: (10.1016/S0085-2538(15)47156-X) Copyright © 2000 International Society of Nephrology Terms and Conditions